The rapid ageing of the European population poses a challenge for healthcare systems. The incidence of cancers will rise as the number of adults aged 65 years and older increases. Moreover, the health status of individuals in this age group is diverse, and thus requires modern oncology to apply an individualised approach to treatment. There is a clear need to develop and validate health assessment tools enabling the identification of specific geriatric issues which might be overlooked by standard assessment methods. The Comprehensive Geriatric Assessment (CGA) is the 'gold standard' for geronto-oncology assessment. However, the complexity of this test has stimulated a search for pre-screening methods able to identify individuals with the potential to gain most from full pre-treatment CGA. Such tools consist of specific tests to evaluate health status in the important functional, psychological, social and cognitive domains. The choice of which tests are best to use within the various screening tools is still a subject of debate. This paper presents a review of the most commonly used tests within various health status domains as well as of the most valuable screening tools.
At the same time, however, the outcomes of treatment of elderly patients suffering from cancer are far from satisfactory. This may be because patients who are over 75-years-old are underrepresented in the group of patients treated aggressively with radical intent. A good illustration of this was described in a study conducted by Aparicio, which revealed that 52 % of elderly patients diagnosed with colorectal cancer had sub-standard cancer treatment, especially with regard to adjuvant therapy. 3 Bastiaannet et al. found striking differences in the relative survival rates of elderly breast cancer patients by comparison with younger patients. 4 Lunbrook oberseved a similar situation in the treatment of small cell lung cancer: only 40 % of patients aged over 75 years were treated with radical chemoradiotherapy compared to 86 % of patients younger than 65 years. 5 This situation has been confirmed in an analysis of relative risk survival in elderly cancer patients, which detected reductions in survival rates with increasing age for most cancer sites. 6 Moreover, the under-representation of older patients in clinical trials makes treatment databases incomplete and makes it impossible to assess the potential for individualised treatment of older patients. This creates a number of difficulties when using evidence-based medicine recommendations and decision-making tools such as Adjuvant! Online, which are reliant on treatment results from large groups of patients which may not include seniors.
The individualisation of treatment is particularly important for patients aged 70-85 years, whose state of health can be very variable. There are no precise definitions of the stages of aging, and date of birth alone clearly cannot be regarded as a sufficient criterion. Some patients may undergo radical treatment with no modifications in therapeutic protocols; however, more vulnerable patients might only tolerate individualised palliative treatment or best supportive care.
For some senior patients the situation is more complicated, as despite having a good performance status before treatment, their physiological reserves may be exhausted, homeostatic balance disturbed and their health deteriorate during treatment.
This group requires an individualised approach to both radical and palliative treatment because of physiological changes due to ageing and their co-morbidities and the interactions between medications used for treating them and any oncological treatment, especially followed by CGA for those patients who need it. Such a two-step evaluation is also recommended by the International Society of Geriatric Oncology (SIOG).
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Purpose of Screening Tools
As the essence of an appropriate evaluation of seniors' health lies in its multidimensionality, there are many screening tools that enable prompt evaluation of various health domains. Such screening divides patients into three groups: healthy and independent patients who can undergo standard treatment with outcomes similar to the rest of the population; patients with moderate impairment requiring slight modification of treatment protocols; and patients whose state of health is most likely to deteriorate, possibly resulting in death. The two latter groups derive benefit from comprehensive geriatric assessment and they should be provided with such an evaluation. Such a division also is in accordance with the widely known and widely used definition of frailty, which categorises patients as healthy, vulnerable or frail depending on the results of the geriatric evaluation. 8 An overview of the most relevant tests in particular health status domains is presented below.
Functional Status
The instruments most frequently used to assess functional condition are the Katz basic activities of daily living (ADL) scale 15 18 and during pre-surgical assessment. 19 The Timed Up Go (TUG) test is used as a frailty marker. It measures the time taken in seconds for a person to get up, walk 10 feet, turn back, walk back and sit down. 20 The simplicity of the test encourages its inclusion into a minimal geriatric assessment process.
Biological and Physiological Status
Ageing triggers widespread changes in processes affecting both lifespan and the body's physiological reserves. Moreover, cancer itself negatively impacts an organism's biological status. An assessment of physiological status is therefore extremely important when planning tailored treatment for older patients.
The most commonly used predictors of treatment tolerance are assessments of liver, renal and bone marrow function. For example, anaemia is correlated with higher mortality in senior 21 and it has been shown that albumin levels are both an indicator of an organism's reserves and an independent mortality risk factor. 22 The degree of toxicity and tolerability of a planned cytotoxic treatment depends on renal function. Plasma creatinine levels and creatinine clearance rates are simple markers of renal function. High levels of interleukin-6 and D-dimers, independent of the presence of cancer, are markers of activated inflammatory and coagulation processes, and thus an indicator of frailty in older persons. 23 Considering all the above, the SIOG task force on CGA recommends integration of biochemical markers such as albumin, haemoglobin levels and creatinine clearance into an assessment of the tolerability of planned treatment in seniors.
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Co-morbidities
Co-morbidities and functional status should be assessed independently. 24 Co-morbid illnesses are are more frequently present in elderly patients than in younger patients, and they have a negative impact on the effects of oncological treatment. 25, 26 A lot of research employs the Charlson Co-morbidity Index (CCI) as a screening test for co-morbidities. The test has proven clinical value; for example, it demonstrated that hypertension can intensify cardiomyopathy associated with trastuzumab and anthracycline treatment. 27, 28 In some situations the Cumulative Illness
Rating Scale for Geriatrics (CIRG-G) is used to classify co-morbidities. The reliability of both tests is comparable. 29 
Psychological State
Between 12 % and 20 % people aged over 65 years experience symptoms of depression. 30 Among the sequelae to depression are lack of appetite -which in turn leads to malnutrition -and poor compliance with treatment -because depressed patients are less motivated to undergo treatment. A frequently-used test for assessing depression is the Hospital Anxiety and Depression Scale (HADS).
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Other tests include the Geriatric Depression Scale (GDS), developed
by Yesevage as a 30-item scale, 32 and the distress thermometer, which is composed of simple questions, answers to which form the basis of which likelihood of depression can be determined.
Polypharmacy
This is directly linked to numbers of co-morbidities. The average number of medications taken by seniors is six and the trend is for this to increase. 7 Often the number of drugs taken is too high, which can be significant in the context of oncological treatments because one therapy may intensify the toxicity of another and produce adverse drug reactions. The Beers list, which contains information on drugs which are potentially toxic for older patients, 33 and the Medication Appropriateness Index (MAI), may be useful measures of appropriate prescribing and optimal pharmacological treatment. Reducing the number of medications taken by the patient is often the first action of a geriatrician before initiating treatment for cancer.
Cognitive Function
A decrease in cognitive function is linked to the stages of ageing.
Approximately one-third of elderly patients experience cognitive disorders, and dementia and delirium are the most frequently-reported dysfunctions in seniors with cognitive disorders. According to Plassman et al., dementia affects 25-48 % of patients aged over 80 years. 34 Dementia can result in decreased compliance with treatment regimens. 34 Additionally, anticancer treatment may worsen cognitive impairment. 45 All of these tests evaluate BMI, weight loss, use of a feeding tube and psychological problems.
Social Functioning
The assessment of patients' social and economic situation is often ignored. However, it should be borne in mind that the costs of oncological treatment may become a financial barrier for a patient both in terms of access to both optimal treatment and support. Lonely 
Frailty
The definition of frailty was proposed by Fried. 47 Frailty is a biological syndrome of decreased reserve and resistance to stressors, causing vulnerability to adverse outcomes. 
Tests Used in Health Status Pre-screening in Seniors Undergoing Oncological Therapy
Many of these tests are used separately in everyday clinical practice and clinical trials. 49, 50 Each of the presented tests has proved its clinical value in the detection of frailty as well as enabling screening of patients to facilitate optimal treatment choice. However, geriatric assessment is complex, even in the case of the minimal preliminary assessment of health, it is, therefore, necessary to apply a set of selected tests which will provide a reliable and quick answer to the question: 'Which patients should undergo detailed CGA assessment?' 51 Such a set of tests -a screening tool that could be used by oncologists within the framework of the multidisciplinary team -should be easy and quick to use. It also ought to identify major problems that cannot be detected by physical examination and, finally, have a high negative predictive value in order to exclude the possibility of vulnerability. [52] [53] [54] [55] The most useful instruments to have been developed and widely-tested are listed in Table 1 and briefly described below.
Minimal Geriatric Assessment (MGA)
Aparicio used the MGA before conducting full CGA on a sample of 21 patients aged over 75 years undergoing treatment for digestive cancer. 56 MGA contains eight simplified modules that evaluate functional, cognitive, psychological, nutrition and social status, as well as co-morbidities, polypharmacy, haemoglobin and creatinine levels and 59 Falci, on the other hand, demonstrated significant inconsistencies between VES-13 and CGA. 60 
The Groningen Frailty Index
This tool assesses disturbances in the physical, cognitive, social and psychological domains. Similar to VES-13, it is based on a clearly defined cut-off point. Nevertheless, in studies its sensitivity and negative predictive value have been found to be relatively low -39 % and 40 %, respectively.
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Tools Dedicated to Risk Assessment
The following tools facilitate therapeutic decision making by measuring the risk of serious complications after a chosen treatment is initiated.
Chemotherapy Risk Assessment Scale for High Age Patients
This scale is the most commonly used and is designed to assess a patient before chemotherapy. It includes IADL, MNA and MMS tests and identifies four groups at risk of hematologic and other severe toxicities. The 32 nd Congress of the European Society of Surgical Oncology is dedicated to promoting the highest standards of surgical care in the management of patients with solid tumours.
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